Ligand Pharmaceuticals

Ligand Pharmaceuticals LGND Stock

$290.51   -2.745131%
Add to favorites
Market Cap
$5.81B
LOW - HIGH [24H]
$287.47 - $301.72
VOLUME [24H]
$58.79K
P/E Ratio
116.67
Earnings per share
$2.49
ISIN
US53220K5048
Price   Prediction

Ligand Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Ligand Pharmaceuticals (LGND) stock price today is 290.51 USD on Tech Market Middle (-2.75% on the day). Updated .

Ligand Pharmaceuticals LGND Financial and Trading Overview

Ligand Pharmaceuticals stock price 290.51 USD
Previous Close 301.71 USD
Open 300.26 USD
Bid 216.6 USD x 200
Ask 396.53 USD x 200
Day's Range 291.61 - 301.96 USD
52 Week Range 175.89 - 326.63 USD
Volume 293.65K USD
Avg. Volume 226.34K USD
Market Cap 5.88B USD
Beta (5Y Monthly) 1.035
PE Ratio (TTM) 117.99598
EPS (TTM) 2.49 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date July 2, 2010
1y Target Est 361.27 USD

LGND Valuation Measures

Enterprise Value 6.58B USD
Trailing P/E 117.99598
Forward P/E 24.577211
PEG Ratio (5 yr expected) 1.53
Price/Sales (ttm) 23.15387
Price/Book (mrq) 6.1100945
Enterprise Value/Revenue 25.938
Enterprise Value/EBITDA 92.113

Trading Information

Ligand Pharmaceuticals Stock Price History

Beta (5Y Monthly) 1.035
52-Week Change 42.59%
S&P500 52-Week Change 10.51%
52 Week High 326.63 USD
52 Week Low 175.89 USD
50-Day Moving Average 302.13 USD
200-Day Moving Average 259.4 USD

LGND Share Statistics

Avg. Volume (3 month) 226.34K USD
Avg. Daily Volume (10-Days) 184.88K USD
Shares Outstanding 20M
Float 19.55M
Short Ratio 9.85
% Held by Insiders 2.27%
% Held by Institutions 117.67%
Shares Short 2.46M
Short % of Float 14.76%
Short % of Shares Outstanding 12.32%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1603:1000

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 20.27%
Operating Margin (ttm) 14.38%
Gross Margin 86.12%
EBITDA Margin 28.15%

Management Effectiveness

Return on Assets (ttm) 1.22%
Return on Equity (ttm) 5.38%

Income Statement

Revenue (ttm) 253.83M USD
Revenue Per Share (ttm) 12.83 USD
Quarterly Revenue Growth (yoy) -31.80%
Gross Profit (ttm) 218.6M USD
EBITDA 71.48M USD
Net Income Avi to Common (ttm) 51.46M USD
Diluted EPS (ttm) 2.49
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 447.4M USD
Total Cash Per Share (mrq) 22.37 USD
Total Debt (mrq) 1.15B USD
Total Debt/Equity (mrq) 120.01 USD
Current Ratio (mrq) 1.215
Book Value Per Share (mrq) 48.086

Cash Flow Statement

Operating Cash Flow (ttm) 91.03M USD
Levered Free Cash Flow (ttm) 62.45M USD

Profile of Ligand Pharmaceuticals

Country United States
State FL
City Jupiter
Address 555 Heritage Drive
ZIP 33458
Phone 858 550 7500
Website https://www.ligand.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 47

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Q&A For Ligand Pharmaceuticals Stock

What is a current LGND stock price?

Ligand Pharmaceuticals LGND stock price today per share is 290.51 USD.

How to purchase Ligand Pharmaceuticals stock?

You can buy LGND shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Ligand Pharmaceuticals?

The stock symbol or ticker of Ligand Pharmaceuticals is LGND.

Which industry does the Ligand Pharmaceuticals company belong to?

The Ligand Pharmaceuticals industry is Biotechnology.

How many shares does Ligand Pharmaceuticals have in circulation?

The max supply of Ligand Pharmaceuticals shares is 20M.

What is Ligand Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Ligand Pharmaceuticals PE Ratio is 116.67068500 now.

What was Ligand Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Ligand Pharmaceuticals EPS is 2.49 USD over the trailing 12 months.

Which sector does the Ligand Pharmaceuticals company belong to?

The Ligand Pharmaceuticals sector is Healthcare.

Ligand Pharmaceuticals LGND included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24201.34 USD —
-0.94
4.68B USD — 24005.47 USD — 24939.62 USD — — 4.68B USD —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech US CapEx Achievers Index CAPEXA US 3759.75 USD —
-1.19
— — 3737.31 USD — 3827.68 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7603.91 USD —
-0.19
— — 7546.09 USD — 7685.86 USD — — — —
us US Tech US 700 Small Cap Value N NQUS700SCVN US 3001.1 USD —
-1.57
— — 2979.8 USD — 3044.65 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 2906.69 USD —
-1.16
— — 2885.86 USD — 2954.75 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3605.34 USD —
-0.97
— — 3577.02 USD — 3690.74 USD — — — —
us US Tech Biotechnology NBI US 6965.89 USD —
-0.08
— — 6905.76 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1317.49 USD —
-0.52
— — 1309.03 USD — 1333.62 USD — — — —
us US Tech Composite Total Return XCMP US 29950.1 USD —
-0.8
— — 29671.6 USD — 30826.03 USD — — — —
us US Tech US 700 Small Cap Value I NQUS700SCV US 2608.01 USD —
-1.58
— — 2589.53 USD — 2645.88 USD — — — —
us US Tech Global Market Composite NQGM US 1835.64 USD —
-0.18
— — 1820.49 USD — 1866.97 USD — — — —
$2.17T
Total marketcap
$71.79B
Total volume
BTC 58.07%   •   ETH 9.95%
Dominance
Select currency